Orthostatic Intolerance, Postural Tachycardia Syndrome
Conditions
Keywords
Exercise, Propanolol, Beta blockers
Brief summary
The main limitation patients with orthostatic intolerance (OI, or postural tachycardia syndrome, POTS) have to exercise is related to their increase in heart rate when standing. Main pharmacological treatment today is aimed at reducing heart rate with the use of betablockers (propanolol), this theoretically could also improve their exercise capacity; if their heart rate do not increase as much with the medication, they could exercise more. In addition, it has been suggested that in healthy volunteers subjected to head down tilt for 2 weeks (situation that produces a simulated transient POTS-like state) a single bout of intense exercise can improve orthostatic tolerance the day after exercising. The mechanisms involved in such response are not that clear but could be an increase in plasma volume already diminished in POTS patients. It seems likely that the same could be true for POTS patients. The purpose of the present study are to pharmacologically improve the amount of exercise POTS patients can perform by reducing their baseline heart rate (specific aim 1) and to evaluate next day heart responses to an acute bout of intense exercise. Therefore, the specific aims of this study are: 1. To test the hypothesis that lowering heart rate response with propanolol will result in an increase in exercise capacity. 2. To test the hypothesis that a single bout of exercise will result in an improvement in orthostatic tolerance the day after exercising.
Detailed description
* Subjects will be studied twice, once after receiving placebo and in a second occasion after receiving propanolol. * An exercise capacity test with estimation of maximal oxygen consumption (VO2 max) will be done within 1 hour of receiving a pill containing placebo and that will be in appearance identical to the one for propanolol. This test will be conducted on a stationary bicycle and the effort will be gradually increased while expired air is measured during exhaustive physical work. The test will last approximately 30 minutes and be conducted in Vanderbilt's Clinical Trial Center. * The day before and the day after the exercise test subjects will be asked to collect urine for 12 hours each time and to keep a record of how much liquid they ingest. * Posture study tests (measurements of heart rate and blood pressure taken while lying down and at intervals for up to 30 minutes while standing) will be done the day before and the day after the exercise test.
Interventions
DRUGPropranolol then Placebo
Propanolol 20 mg, given orally within 1 hour prior to exercising
DRUGPlacebo then Propranolol
Placebo, matching pill given orally within 1 hour prior to exercising
Sponsors
Vanderbilt University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Meet diagnostic criteria of POTS (Raj, et al., 2005) * Age between 18-65 years * Male and female are eligible (although the majority of patients POTS are female). * Able and willing to provide informed consent
Exclusion criteria
* Presence of medical conditions that can explain postural tachycardia (e.g., dehydration, medications) * Pregnancy * Other factors which in the investigator's opinion would prevent the subject from completing the protocol. * Patients who are bedridden or chair-ridden.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximal Oxygen Consumption Capacity (VO2 Max) | Over approximately 30 minutes, within 2 hours of receiving each intervention. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Propranolol Then Placebo Active treatment
Propranolol then Placebo: Propanolol 20 mg, given orally within 1 hour prior to exercising | 8 |
| Placebo Then Propranolol Placebo Treatment
Placebo then Propranolol: Placebo, matching pill given orally within 1 hour prior to exercising | 4 |
| Total | 12 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Placebo Then Propranolol | Propranolol Then Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 8 Participants | 12 Participants |
| Age, Continuous | 32 Years STANDARD_DEVIATION 2 | 31 Years STANDARD_DEVIATION 3 | 32 Years STANDARD_DEVIATION 3 |
| Region of Enrollment United States | 4 participants | 8 participants | 12 participants |
| Sex: Female, Male Female | 4 Participants | 8 Participants | 12 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 8 | 0 / 4 |
| serious Total, serious adverse events | 0 / 8 | 0 / 4 |
Outcome results
Primary
Maximal Oxygen Consumption Capacity (VO2 Max)
Time frame: Over approximately 30 minutes, within 2 hours of receiving each intervention.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Propranolol | Maximal Oxygen Consumption Capacity (VO2 Max) | 27.6 mL/kg/min | Standard Error 1 |
| Placebo | Maximal Oxygen Consumption Capacity (VO2 Max) | 24.5 mL/kg/min | Standard Error 0.7 |